Two new strains
Microbiome Center is continuously searching worldwide for interesting other substances and strains that you can use in microbiome therapy. We’ve added two new spore-forming probiotic strains to the palette for you to choose from. The first is a Bacillus clausii which, due to its spore-forming properties, is very stable and has excellent gastrointestinal survival (1). This strain has been clinically studied in diarrhea (2,3). There are also tentative indications for a possible effect in uremia (4) and for an inhibitory effect on the pathogenic bacterium Bacillus cereus (5).
The second strain is a Bacillus coagulans. This strain shows a large effect on constipation in a well-performed RCT (6). There are also several clinical studies showing a beneficial effect in IBS (7-9). There is also evidence for a positive effect for the related complaint of abdominal pain, albeit somewhat less consistently (7-12). In addition, there are some indications from clinical studies that this strain is effective in, among others, SIBO (13) and bacterial vaginosis (oral use) (14).
More information about these and all other ingredients can be found in the MC treatment network under the (i) button under the ingredients.
More evidence for the role of the microbiome in multiple sclerosis
There have been several indications that the gut microbiome plays a role in the etiology of multiple sclerosis (MS), such as substances of bacterial origin in the blood and the presence of bacteria in the brains of deceased patients (15). A recently published study adds another clue. In MS patients, immunoglobulin A (IgA) was found in cerebrospinal fluid (16). B cells expressing IgA were also found in the brains of deceased patients, especially at lesion sites. It was striking that the B cells with IgA expression in the cerebrospinal fluid do respond to intestinal bacteria, but not to antigens from the brain. This indicates that these B cells originated from the gut and migrated to the cerebrospinal fluid.
This research suggests that during the active phase of MS B cells that respond to gut bacteria migrate to and are active in cerebrospinal fluid and the brain. It seems plausible that there is an important role for an intestinal barrier here. Immune-modulating probiotic strains may play a role here, and some initial animal and clinical studies of probiotics show initial cautious positive effects (17).
References:
- https://doi.org/10.3389/fmicb.2020.01010
- https://doi.org/10.3920/BM2018.0094
- https://doi.org/10.3920/BM2012.0034
- https://doi.org/10.1007/s12602-019-09540-x
- https://doi.org/10.4014/mbl.1903.03005
- https://doi.org/10.1007/s12602-019-09542-9
- https://doi.org/10.3920/BM2017.0129
- https://doi.org/10.1038/s41598-019-48554-x
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129566/
- https://doi.org/10.5812/ircmj.17(4)2015.23844
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285933/
- https://www.researchgate.net/publication/282188545_Efficacy_of_Bacillus_coagulans_strain_unique_IS-2_in_the_treatment_of_patients_with_acute_diarrhea
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311312/
- https://doi.org/10.1007/s12088-011-0233-z
- https://dev.studioboszkers.nl/microbiome-center/Medici/MS,-Parkinson,-Alzheimer/
- https://doi.org/10.1126/sciimmunol.abc7191
- https://doi.org/10.1186/s12974-019-1611-4